ALEMBIC ARIPIPRAZOLE, ARILEM ARIPIPRAZOLE, ARILEMBIC ARIPIPRAZOLE, ARIPIC ARIPIPRAZOLE, ARIPIPRAZOLE AGH, ARIPIPRAZOLE AGHL, ARIPIPRAZOLE APL, ARIPIPRAZOLE APPL, ARIPITO ARIPIPRAZOLE, ARITRIEVAL ARIPIPRAZOLE, ARIVEL ARIPIPRAZOLE, PIVELON ARIPIPRAZOLE (Ale
Product name
ALEMBIC ARIPIPRAZOLE, ARILEM ARIPIPRAZOLE, ARILEMBIC ARIPIPRAZOLE, ARIPIC ARIPIPRAZOLE, ARIPIPRAZOLE AGH, ARIPIPRAZOLE AGHL, ARIPIPRAZOLE APL, ARIPIPRAZOLE APPL, ARIPITO ARIPIPRAZOLE, ARITRIEVAL ARIPIPRAZOLE, ARIVEL ARIPIPRAZOLE, PIVELON ARIPIPRAZOLE
Date registered
Evaluation commenced
Decision date
Approval time
154 working days (255)
Active ingredients
aripiprazole
Registration type
New generic medicine
Indication
ALEMBIC ARIPIPRAZOLE, ARILEM ARIPIPRAZOLE, ARILEMBIC ARIPIPRAZOLE, ARIPIC ARIPIPRAZOLE, ARIPIPRAZOLE AGH, ARIPIPRAZOLE AGHL, ARIPIPRAZOLE APL, ARIPIPRAZOLE APPL, ARIPITO ARIPIPRAZOLE, ARITRIEVAL ARIPIPRAZOLE, ARIVEL ARIPIPRAZOLE, PIVELON ARIPIPRAZOLE (uncoated tablet) is indicated for the treatment of:
- Schizophrenia including maintenance of clinical improvement during continuation therapy.
- Acute treatment of manic or mixed episodes associated with Bipolar I Disorder in adults as monotherapy and in combination with lithium or valproate;
- Maintenance treatment of manic or mixed episodes in Bipolar I Disorder in adults as monotherapy.